Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Down 25.8% in June

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) was the recipient of a large drop in short interest in June. As of June 30th, there was short interest totalling 3,130,000 shares, a drop of 25.8% from the June 15th total of 4,220,000 shares. Based on an average daily trading volume, of 802,000 shares, the days-to-cover ratio is currently 3.9 days. Currently, 5.7% of the shares of the stock are sold short.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Farallon Capital Management LLC grew its holdings in Agios Pharmaceuticals by 34.1% in the 1st quarter. Farallon Capital Management LLC now owns 5,590,602 shares of the biopharmaceutical company's stock worth $163,469,000 after acquiring an additional 1,423,000 shares during the last quarter. Vanguard Group Inc. grew its holdings in Agios Pharmaceuticals by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 5,572,021 shares of the biopharmaceutical company's stock worth $162,926,000 after acquiring an additional 44,583 shares during the last quarter. Armistice Capital LLC grew its holdings in Agios Pharmaceuticals by 6.0% in the 4th quarter. Armistice Capital LLC now owns 3,524,000 shares of the biopharmaceutical company's stock worth $78,479,000 after acquiring an additional 200,000 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Agios Pharmaceuticals by 5.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,596,764 shares of the biopharmaceutical company's stock worth $57,832,000 after acquiring an additional 137,873 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in Agios Pharmaceuticals by 23.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company's stock worth $58,861,000 after acquiring an additional 388,381 shares during the last quarter.

Agios Pharmaceuticals Stock Performance

NASDAQ:AGIO traded up $1.49 during trading hours on Friday, reaching $45.88. The company's stock had a trading volume of 736,087 shares, compared to its average volume of 652,881. The firm has a market capitalization of $2.60 billion, a price-to-earnings ratio of -7.26 and a beta of 0.79. The firm has a 50-day simple moving average of $40.35 and a 200-day simple moving average of $32.03. Agios Pharmaceuticals has a 1 year low of $19.80 and a 1 year high of $49.06.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.65) by $0.20. The business had revenue of $8.19 million for the quarter, compared to analyst estimates of $8.37 million. Agios Pharmaceuticals had a negative net margin of 1,199.26% and a negative return on equity of 41.41%. The company's revenue was up 46.0% on a year-over-year basis. During the same quarter last year, the firm earned ($1.47) EPS. Equities analysts anticipate that Agios Pharmaceuticals will post -2.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Royal Bank of Canada raised their price objective on shares of Agios Pharmaceuticals from $44.00 to $53.00 and gave the company an "outperform" rating in a research report on Tuesday, June 4th. StockNews.com upgraded shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday. Cantor Fitzgerald reiterated an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Monday, June 17th. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $46.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, June 13th. Finally, The Goldman Sachs Group lifted their target price on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a "neutral" rating in a research report on Tuesday, June 4th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Agios Pharmaceuticals has a consensus rating of "Hold" and an average target price of $50.67.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.